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Abstract. Associations of functional single nucleotide poly-
morphisms in cytochrome P450 1B1, epoxide hydrolase 1,
NAD(P)H:quinone oxidoreductase 1, glutathione S-trans-
ferase Pi-1 and deletions of glutathione S-transferases Mu-1
and ı-1 with colorectal cancer risk were investigated in a
hospital-based case-control study on 495 matched pairs of
Czech Caucasians. Polymorphisms were assessed by poly-
merase chain reaction restriction fragment length polymor-
phism-based methods, allele-specific multiplex and allelic
discrimination by real-time polymerase chain reaction.
Carriers of variant Ser allele in codon 453 of cytochrome
P450 1B1 (rs1800440) were at a significantly lower risk of
colorectal cancer compared to carriers of the wild-type allele
(adjusted odds ratio, aOR=0.68, CI=0.51-0.89, p=0.006). The
combination of polymorphisms in codons 453 and 432
(rs1056836) of cytochrome P450 1B1 further increased the
protective effect (aOR=0.53, CI=0.34-0.83, p=0.005). The
glutathione S-transferase Mu-1 deletion was associated with a
moderately elevated colorectal cancer risk (aOR=1.30,
CI=1.01-1.68, p=0.044). Combination of glutathione S-
transferase Mu-1 and ı-1 deletion was associated with a
significantly higher colorectal cancer risk compared to the
presence of both full-length genes (aOR=1.58, CI=1.01-2.47,
p=0.044). Genetic polymorphisms in glutathione S-
transferase Pi-1, NAD(P)H:quinone oxidoreductase 1, epoxide
hydrolase 1 and deduced epoxid hydrolase 1 activity did not
modify the risk of colorectal cancer. These results provide
further evidence that interaction between metabolic gene
variants contributes to colorectal carcinogenesis.
Introduction
Worldwide, colorectal cancer (CRC) is the third most common
cancer with an estimated 1,023,256 newly diagnosed cases
and 529,020 deaths per year (1). In terms of CRC incidence,
the Czech Republic ranks second in Europe (2) and the
number of new cases is rapidly increasing (3). It is postulated
that 20-30% of all patients with CRC have a family history of
CRC that suggests a genetic contribution, common exposures
among family members, or a combination of both (4). Red
meat consumption has frequently shown an association with
an increased risk of CRC. It has been proposed that this risk
may be due to carcinogenic polycyclic aromatic hydrocarbons
(PAHs) and heterocyclic amines produced when meat is
cooked at high temperatures (5). These chemicals, aromatic
amines and nitroso compounds may be found in tobacco
smoke which is also recognized as a potential CRC risk
factor (6). Metabolism of these chemicals is performed by
the genetically variable xenobiotic-metabolizing enzymes
(XME). Briefly, phase I XME such as cytochromes P450
(e.g. CYP1B1), epoxide hydroxylases (e.g. EPHX1) or
oxidoreductases (e.g. NQO1) produce reactive metabolites
which are then conjugated by transferases (e.g. GSTM1,
GSTP1, GSTT1) to polar compounds in phase II reactions.
Phase II metabolites may be further processed (metabolism,
cleavage, hydrolysis, acetylation, etc.) by phase III XME (7).
Genetic polymorphisms in XME genes that alter the expression
and activity of the protein products are thus strong candidates
for CRC risk modifiers.
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Cytochromes P450 (CYPs) are the most important
enzymes involved in the phase I of biotransformation. CYPs
catalyze a large number of reactions modifying dietary and
smoking-derived pre-carcinogens and participate in the meta-
bolism of endogenous compounds including hormones and
bile acids (8). CYP1B1 plays an important role in activating
PAHs or heterocyclic amines to reactive metabolites that cause
DNA damage. Polymorphisms in CYP1B1 have recently been
associated with CRC susceptibility (9). Epoxide hydrolase
(EPHX1) catalyzes the hydrolysis of major metabolites of
PAHs (epoxides) to less reactive trans-dihydrodiols. Two
common alleles of EPHX1 in codons 113 (site T337C, amino
acid change Tyr113His, dbSNP: rs1051740) and 139
(A415G, His139Arg, rs2234922) affect enzyme activity (10).
However, a lack of association of EPHX1 polymorphisms
with CRC risk has been reported (11,12). NAD(P)H:quinone
oxidoreductase (NQO1) is an obligate two-electron reductase
that can either bioactivate or detoxify quinones and may
play an important role in chemoprevention (13). An NQO1
polymorphism in codon 187 (C609T, Pro187Ser, rs1800566),
resulting in an inactive enzyme, has been associated with the
risk of CRC (12,14) and sporadic distal colorectal adenomas
(15). Glutathione S-transferases (GST), GSTM1, GSTP1 and
GSTT1 belong to the most frequently studied XMEs in mole-
cular epidemiology of cancer. Large genomic deletions (null
genotype) of GSTM1 and GSTT1 result in a complete lack
of enzyme activities. A GSTP1 polymorphism in codon 105
(A313G, Ile105Val, rs1695) generates an enzyme with
different heat stability and substrate affinity (16). A study by
Ferraz et al (17) suggested that GSTT1 and GSTP1 could
play a role in the occurrence of KRAS and TP53 mutations in
CRC and a report by Moore et al (18) showed associations
between colorectal adenomas and GSTM1-plus and GSTT1-
null among smokers. Recently, we have reported an asso-
ciation of combined EPHX1, GSTM1 and GSTT1 polymor-
phisms with genetic damage (higher DNA single-strand
breaks) in general Czech population (19).
This study evaluated associations between polymor-
phisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1, GSTT1
and risk of CRC in a relatively homogeneous population with
one of the highest CRC incidences.
Materials and methods
Subjects. The study population comprised 495 patients
with CRC (cases) and 495 individuals with no evidence of
colorectal malignancy (controls). Eligibility criteria for study
participation of cases and controls included Czech origin,
ages 29 years or more, and consent to provide biological
samples for genetic analysis. To reduce selection bias, only
those subjects with no previous diagnosis were included in
the study to avoid inclusion of patients with chronic diseases
who may be repeatedly admitted to hospital and modify their
habits because of their disease. Recruitment of participants
was coordinated by Department of Oncology, General
Teaching Hospital in Prague in the period between September
2004 and February 2006. Cases with histologically-confirmed
positively-diagnosed CRC were recruited from patients visiting
nine oncology departments (two in Prague, one in Benesov,
Brno, Liberec, Ples, Pribram, Usti nad Labem and Zlin). The
participating hospitals are located throughout the Czech
Republic; therefore, it is reasonable to expect, that the cases
represent the general Czech population. During the study
period, a total of 968 CRC cases provided consent to parti-
cipate in the study. Of the recruited group, 16 cases met the
Amsterdam criteria I and II for hereditary CRC and were
excluded from the study (20). Four hundred and fifty-seven
cases were excluded because eligibility criteria were not met
or incomplete lifestyle and potential risk factor information
was available or biological material was lacking.
Controls were recruited over the same period as the cases
from individuals undergoing colonoscopy for various gastro-
intestinal complaints (macroscopic bleeding, positive fecal
occult blood test, hemorrhoids, abdominal pain of unknown
origin) from five large gastroenterological departments
(Prague, Brno, Jihlava, Liberec, and Pribram). Due to the high
incidence of CRC in the Czech Republic, colonoscopy is
highly recommended and widely practiced. Controls were
selected from those showing negative colonoscopy results
for malignancy or idiopathic bowel diseases. Controls had
no diagnosis of chronic disease necessitating repeated admit-
tance to hospital (21). One hundred and ninety-three controls
were excluded because eligibility criteria were not met or
incomplete lifestyle and potential risk factor information
was available or biological material was lacking. In the last
step, controls were matched on the basis of age (±2.5 years)
to cases and thus 495 case-control pairs were established
for this study. Study subjects provided by self-guided ques-
tionnaire information on their education, living area, lifestyle
habits, body mass index (BMI), diabetes, family/personal
history of cancer and long-term (at least 6 consecutive months)
drug use. The case-control set was not collected specifically
for the present study, but for previous studies on the risk of
genetic polymorphisms in different pathways, as recently
described (21).
All subjects were informed and gave written consent to
participate in the study. The design of the study was approved
by the Ethics Committee of the Institute of Experimental
Medicine, Prague, Czech Republic.
Genotyping. Blood was collected during diagnostic procedures
using tubes with K3EDTA anticoagulant. DNA was isolated
from lymphocytes using the phenol/chloroform extraction
method as described earlier (22). Polymorphisms in CYP1B1
(Leu432Val, dbSNP: rs1056836 and Asn453Ser, rs1800440),
GSTM1 (gene deletion) and GSTT1 (gene deletion) were
assayed by published methods: polymerase chain reaction
(PCR) restriction fragment length polymorphism and allele-
specific multiplex PCR (23). Oligonucleotide primers were
synthesized by Generi Biotech (Hradec Kralove, Czech
Republic). Polymorphisms in GSTP1 (Ile105Val, rs1695),
NQO1 (Pro187Ser, rs1800566) and EPHX1 (His113Tyr,
rs1051740 and Arg139His, rs2234922) were assayed
by allelic discrimination with TaqMan Drug Metabolism
Genotyping Assays (Applied Biosystems, Foster City, CA)
using real time PCR in RotorGene 6000 (Corbett Research,
Brisbane, Australia). The TaqMan assays (GSTP1, Ile105Val,
C-3237198_20; NQO1, Pro187Ser, C-2091255_30; EPHX1,
His113Tyr, C-14938_30 and Arg139His, C-11638783_30)
were performed according to manufacturer's instructions
HLAVATA et al:  XME POLYMORPHISMS AND COLORECTAL CANCER1348
1347-1353.qxd  24/9/2010  09:43 Ì  ™ÂÏ›‰·1348
(Applied Biosystems). EPHX1 enzyme activity was inferred
according to the results of His113Tyr and Arg139His geno-
typing (22). For quality control, 10% of the samples were
randomly selected and re-genotyped with 100% concordance
of the results.
Statistical analysis. In the first round of analyses, Hardy-
Weinberg equilibrium was assessed for the control group.
The distribution of genotypes did not significantly deviate
from equilibrium. The differences in distribution of the geno-
types between cases and controls were assessed from 2x2
tables and Pearson's ¯2 test was used to test significance. We
further employed binary logistic regression to model the
association between the risk of CRC and the studied geno-
types and their combinations while adjusting for the effects
of the age at recruitment, sex, BMI, smoking, alcohol con-
sumption, living area and education. The two-sided p<0.05
was considered statistically significant. Analyses were per-
formed using Win SPSS v13.0 (SPSS, Chicago, IL). Our study
had 85% power to detect odds ratio (OR) 1.5 at ·=0.05 for the
0.15 rare allele frequency of CYP1B1 codon 453 (the lowest
frequency from the analyzed polymorphisms). The rest of the
studied polymorphisms had higher power to detect this OR.
Results
Characteristics of study population. This case-control study
is based on a comparison of 495 CRC cases and 495 controls.
Basic characteristics and crude comparison of the cases and
controls with respect to the potential confounders are given
in Table I. The cases and controls differ significantly in their
smoking status, education and living area. Despite the effort
to match the controls and cases for age, the controls tend to
be slightly younger than the cases (mean difference 1.7 years,
p=0.036). A biological significance of this age difference is
unlikely; nevertheless, when evaluating the effects of studied
genotypes and their combinations on the CRC risk, we
accounted for age and for effects of the other potential risk
factors by means of the binary logistic regression.
Associations of polymorphisms and selected gene com-
binations with colorectal cancer risk. The summary of crude
and adjusted odds ratios (cOR and aOR), 95% confidence
intervals (CI) and corresponding p-values is given in Tables II
and III. Carriers of the variant Ser allele in codon 453 of
CYP1B1 were at significantly lower risk of CRC than the
carriers of the wild-type (cOR=0.74, 95% CI=0.56-0.96,
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Table I. Characteristics of the studied population.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Cases Controls cORa 95% CIa P-value
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Gender
Female 206 (41.6) 230 (46.5) 1.00 (reference)
Male 289 (58.4) 265 (53.5) 1.22 0.95-1.57 0.125a
Age at recruitment (years)
Mean ± SD 57.2±11.5 55.5±13.8 1.01b 1.00-1.02 0.036c
Range 23-89 25-91
BMI
Mean ± SD 26.6±4.3 26.7±4.5 1.00 0.96-1.03 0.821c
Range 13.1-44.9 16.6-44.3
Smoking status
Never smokers 243 (49.1) 195 (39.4) 1.00 (reference)
Smokers 74 (14.9) 76 (15.4) 0.78 0.54-1.13 0.193a
Ex-smokers >5 years 99 (20.0) 76 (15.4) 1.05 0.73-1.49 0.806a
Ex-smokers ≤5 years 47 (9.5) 17 (3.4) 2.22 1.24-3.99 0.008a
Missing 32 (6.5) 131 (26.4) 0.20 0.13-0.30 <0.001a
Education
Basic 112 (22.6) 89 (18.0) 1.00 (reference)
High school 174 (35.2) 200 (40.4) 0.69 0.49-0.98 0.036a
University 41 (8.3) 72 (14.5) 0.45 0.28-0.73 0.001a
Missing 168 (33.9) 134 (27.1) 1.00 0.70-1.43 0.984a
Living area
Countryside 98 (19.8) 79 (16.0) 1.00 (reference)
Suburban 50 (10.1) 78 (15.8) 0.52 0.33-0.82 0.005a
Urban 207 (41.8) 212 (42.8) 0.79 0.55-1.12 0.184a
Missing 140 (28.3) 126 (25.4) 0.90 0.61-1.31 0.572a
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Percentages in brackets. aPearson ¯2 test; cOR, crude odds ratio; 95% CI, 95% confidence interval; bincrease of risk per one unit change in age at recruitment;
cANOVA test.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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Table II. Associations of polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTT1 and GSTP1 with colorectal cancer risk.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Gene Genotype Cases Controls cORa 95% CIa P-valuea aORb 95% CIb P-valueb
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
CYP1B1 Leu/Leu 174 (35.2) 155 (31.3) 1.00 (reference) 1.00 (reference)
codon 432 Leu/Val 237 (47.9) 262 (52.9) 0.81 0.6 -1.07 0.129 0.84 0.63-1.11 0.222
Val/Val 84 (17.0) 78 (15.8) 0.96 0.66-1.40 0.829 1.04 0.70-1.52 0.862
Leu/Val+Val/ 321 340 0.84 0.65-1.10 0.200 0.88 0.67-1.16 0.360
Val
qValc 0.41 0.42
CYP1B1 Asn/Asn 353 (71.3) 320 (64.6) 1.00 (reference) 1.00 (reference)
codon 453 Asn/Ser 134 (27.1) 163 (32.9) 0.75 0.57-0.98 0.035 0.69 0.52-0.91 0.010
Ser/Ser 8 (1.6) 12 (2.4) 0.60 0.24-1.50 0.277 0.52 0.21-1.29 0.157
Asn/Ser+Ser/ 142 175 0.74 0.56-0.96 0.025 0.68 0.51-0.89 0.006
Ser
qSerc 0.15 0.19
CYP1B1 Leu/Leu+Asn/ 103 77 1.00 (reference) 1.00 (reference)
diplotype Asn
Val+Serd 71 97 0.55 0.36-0.84 0.005 0.53 0.34-0.83 0.005
NQO1 Pro/Pro 346 (69.9) 344 (69.5) 1.00 (reference) 1.00 (reference)
codon 187 Pro/Ser 134 (27.1) 138 (27.9) 0.97 0.73-1.28 0.806 1.00 0.75-1.33 0.997
Ser/Ser 15 (3.0) 13 (2.6) 1.15 0.54-2.45 0.722 1.32 0.61-2.85 0.481
Pro/Ser+Ser/ 149 151 0.98 0.75-1.29 0.890 1.03 0.78-1.35 0.853
Ser
qSerc 0.17 0.17
GSTM1 plus 228 (46.1) 254 (51.3) 1.00 (reference) 1.00 (reference)
(deletion) null 267 (53.9) 241 (48.7) 1.23 0.96-1.58 0.098 1.30 1.01-1.68 0.044
GSTT1 plus 392 (79.2) 395 (79.8) 1.00 (reference) 1.00 (reference)
(deletion) null 103 (20.8) 100 (20.2) 1.04 0.76-1.41 0.813 1.07 0.78-1.47 0.664
GSTP1 Ile/Ile 223 (45.1) 224 (45.3) 1.00 (reference) 1.00 (reference)
codon 105 Ile/Val 229 (46.3) 226 (45.7) 1.02 0.78-1.32 0.895 1.01 0.77-1.32 0.944
Val/Val 43 (8.7) 45 (9.1) 0.96 0.61-1.52 0.861 1.01 0.63-1.61 0.969
Ile/Val+Val/ 272 271 1.01 0.79-1.30 0.949 1.01 0.78-1.30 0.942
Val
qValc 0.32 0.32
EPHX1 Tyr/Tyr 221 (44.6) 231 (46.7) 1.00 (reference) 1.00 (reference)
codon 113 Tyr/His 224 (45.3) 212 (42.8) 1.10 0.85-1.44 0.460 1.09 0.83-1.43 0.534
His/His 50 (10.1) 52 (10.5) 1.01 0.65-1.55 0.982 0.96 0.62-1.49 0.869
Tyr/His+His/ 274 264 1.09 0.85-1.39 0.523 1.06 0.82-1.37 0.635
His
qHisc 0.33 0.32
EPHX1 His/His 297 (60.0) 290 (58.6) 1.00 (reference) 1.00 (reference)
codon 139 His/Arg 173 (34.9) 183 (37.0) 0.92 0.71-1.20 0.551 0.89 0.68-1.17 0.411
Arg/Arg 25 (5.1) 22 (4.4) 1.11 0.61-2.01 0.732 1.06 0.58-1.96 0.845




Number of genotype carriers presented (percentages in brackets). aCrude odds ratios (cOR) and 95% confidence intervals (95% CI); bodds ratios (aOR) and 95%
confidence intervals (95% CI) adjusted for age at diagnosis, gender, smoking, education and living area; cfrequency of variant allele carriage in studied subgroups;
dcarriers of at least one variant allele in codons 432 and 453.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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p=0.025, Table II). The protective effect was more apparent,
when the carriers of the wild-type genotype in both codons
432 and 453 of CYP1B1 were combined and compared to
carriers of the variant alleles in these codons (cOR=0.55, 95%
CI=0.36-0.84, p=0.005, Table II). The adjusted analyses of
the polymorphism in codon 453 of CYP1B1 and the codon
432-453 diplotype also showed significant associations with
CRC risk (aOR=0.68, 95% CI=0.51-0.89, p=0.006 and
aOR=0.53, 95% CI=0.34-0.83, p=0.005, respectively, Table II).
The deletion of GSTM1 was associated with a moderate
increase in the CRC risk (cOR=1.23, 95% CI=0.96-1.58,
p=0.098, Table II). This association reached the level of
statistical significance after adjustment (aOR=1.30, 95%
CI=1.01-1.68, p=0.044, Table II). Neither genetic polymor-
phisms in EPHX1, NQO1, GSTP1 and GSTT1 nor the inferred
EPHX1 activity modified CRC risk (results not shown). In
agreement with our previous studies (19,22), the effect of
functionally-relevant combinations of polymorphisms in
GSTs and EPHX1 was also analyzed. Of the analyzed
combinations (GSTM1-GSTT1, GSTM1-GSTP1, GSTT1-
GSTP1, GSTM1-EPHX1-activity, GSTT1-EPHX1-activity, and
GSTP1-EPHX1-activity), none were significantly associated
with the CRC risk in crude analyses (Table III). However,
adjusted analyses showed a significantly higher risk in
individuals carrying the combination of GSTM1-null and
GSTT1-null genotype when compared to GSTM1-plus and
GSTT1-plus carriers (aOR=1.58, 95% CI=1.01-2.47,
p=0.044, Table III). Smoking did not modify the observed
effects of any studied polymorphisms (results not shown).
Discussion
The Czech Republic has one of the highest CRC incidences
worldwide. Possible factors contributing to the high CRC
incidence in the Czech Republic may involve dietary habits,
e.g. high content of fat containing diet based on fried and
roasted pork meat (24), relatively homogeneous genetic back-
ground (25), and a good capture of CRC cases due to well
established cancer registry.
The major purpose for defining genetic markers asso-
ciated with cancer disease is to target preventive screening
programs to high-risk individuals (FOBT, colonoscopy or
flexible sigmoidoscopy in CRC) and interventions to prevent
the development of cancer (dietary changes, cessation of
smoking, avoidance of obesity). The study of association of
XME polymorphisms with cancer needs to be controlled very
carefully in terms of exposure, age and gender of participants
(23,26). This was our primary focus during the statistical
analyses. Most of the variables (age, gender, BMI and
smoking) included in our statistical analyses as potential
confounders are so-called obligatory confounders in the field
of cancer epidemiology (27-29). Education was included as a
surrogate measure for socio-economic status of study parti-
cipants, which is also considered to be potentially important
confounder. The living area (urban vs. rural) was selected
as a surrogate measure of some features of lifestyle and
environmental exposures. In the Czech Republic, both living
area and education are commonly used for this purpose (30).
We have used the colonoscopy-negative control group to
ensure disease-free control individuals, as a negative colono-
scopy result serves as the best available proof of the absence
of CRC (31).
Variant allele frequencies of the studied XME polymor-
phisms in the control group did not significantly differ from
previously published data from the Czech population (22,23).
Polymorphisms in EPHX1 (neither single polymorphisms nor
their combinations which serve for enzyme activity deduction),
GSTP1 and NQO1 did not modify CRC risk. The results
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Table III. Associations of combinations of polymorphisms in EPHX1, GSTM1, GSTT1 and GSTP1 with colorectal cancer risk.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Genotypes Cases Controls cORa 95% CIa P-valuea aORb 95% CIb P-valueb
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
GSTM1-plus+GSTT1-plus 186 200 1.00 (reference) 1.00 (reference)
GSTM1-null+GSTT1-null 61 46 1.43 0.93-2.20 0.107 1.58 1.01-2.47 0.044
GSTM1-plus+GSTP1-Ile/Ile 148 116 1.00 (reference) 1.00 (reference)
GSTM1-null+GSTP1-Valc 104 133 1.24 0.87-1.77 0.231 1.26 0.87-1.80 0.220
GSTT1-plus+GSTP1-Ile/Ile 174 178 1.00 (reference) 1.00 (reference)
GSTT1-null+GSTP1-Valc 54 54 1.02 0.67-1.57 0.918 1.09 0.70-1.71 0.694
GSTM1-plus+EPHX1-medium/high 147 168 1.00 (reference) 1.00 (reference)
GSTM1-null+EPHX1-low 96 84 1.31 0.91-1.89 0.154 1.36 0.93-1.97 0.111
GSTT1-plus+EPHX1-medium/high 260 263 1.00 (reference) 1.00 (reference)
GSTT1-null+EPHX1-low 38 45 1.20 1.75-1.91 0.446 1.27 0.79-2.05 0.330
GSTP1-Ile/Ile+EPHX1-medium/high 142 146 1.00 (reference) 1.00 (reference)
GSTP1-Valc+EPHX1-low 96 92 1.07 0.74-1.55 0.708 1.07 0.73-1.56 0.727
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Number of genotype carriers presented. aCrude odds ratios (cOR) and 95% confidence intervals (95% CI); bodds ratios (aOR) and 95% confidence intervals
(95% CI) adjusted for age at diagnosis, gender, smoking, education and living area; ccarriers of at least one variant allele, i.e. genotypes Ile/Val or Val/Val
in GSTP1.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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obtained in this study correspond to some previous studies
[EPHX1, negative results (11,12,15)] but do not confirm
findings published by others [EPHX1 as a CRC protective
factor; (32) and NQO1 as a CRC risk factor (12,14,33)]. It is
generally true that population-specific genetics and/or lifestyle
differences together with variations in study design, study
power and methodology may cause discrepancies among
case-control studies. It is essential to reproduce results on
adequate samples sizes from ethnically well-defined popu-
lations.
In our study, GSTM1-null genotype increased the CRC
risk 1.3-fold alone and 1.6-fold in combination with the
inheritance of GSTT1-null genotype. Similarly to our study,
GSTM1-null and GSTT1-null genotypes were identified as
CRC risk factors (OR=1.62, CI=1.06-2.46 and OR=1.64,
OR=1.10-2.59, respectively) in the Turkish population (34).
The combination of polymorphism in GSTP1 with GSTM1-
null was associated with higher CRC risk in a Japanese study
(35). Elevation in CRC risk by inheritance of the GSTM1-
null allele (OR=1.41) was also observed amongst UK CRC
patients, although this effect did not reach statistical signi-
ficance (36). However, no association of GSTM1 or GSTT1
with CRC risk was observed in the Scottish population (37).
The combination of GSTM1 and GSTT1 deletions was asso-
ciated with higher risk of developing a transverse or rectal
tumor (34). Functional study on 208 German individuals, who
underwent colonoscopy, observed significant decrease in GST
activity, GSH levels and GSTP1 expression from proximal to
distant colon (38). Moreover, GSTP1 seems highly relevant
for CRC therapy as the GSTP1 polymorphism in codon 105
was associated in a dose-dependent fashion with increased
survival of patients with advanced CRC receiving 5-FU/
oxaliplatin chemotherapy (39). Thus, in addition to the
relevance for predictive testing, there may be a role of variants
in XME genes as predictive therapeutic markers.
A study of Huang et al (40) on African Americans
and American Caucasians found that GSTT1 and GSTM1
polymorphisms may be slightly related to the CRC risk and
that there may be ethnic differences in gene-smoking inter-
actions. However, our study in the Czech population did not
find any modifying effect of smoking. According to the study
of Skjelbred et al (41), GSTM1, GSTP1 and EPHX1 may
modify the effect of dietary factors on the risk of developing
CRC and colorectal adenoma. Moore et al (18) published the
association between advanced villous colorectal adenomas
(precursors of CRC) and GSTM1-plus and GSTT1-null in
smokers. A recent meta-analysis supports the role of GSTM1-
null as a potential CRC risk factor, especially in Caucasian
populations (42). Published results along with our data
suggest that colorectal carcinogenesis may be partly driven
by interaction between XME and environmental factors.
The exact nature of these interactions needs to be studied in
detail. Moreover, various populations and subpopulations
might have a higher CRC risk and the underlying mechanisms
may differ.
Carriers of the variant allele in codon 453 of CYP1B1
(rs1800440) indicated a lower CRC risk. Analysis of the
CYP1B1 diplotype further underlined this effect. Our study
adds additional information to recently reported observations.
CYP1B1 was found to be a CRC risk associated gene by
Bethke et al (43). Fan et al (44) suggested a significant
interaction between CYP1B1 and cigarette smoking in a
CRC case-only study in the Chinese population. Further-
more, the association between CRC risk and polymorphisms
in CYP1B1 (and also CYP1A1 and CYP1A2) was observed
in the case-control study of Landi et al (45). Although we
identified the rs1800440 polymorphism in CYP1B1 as a
potential CRC risk-associated allele, the two previously
published studies did not associate this SNP with CRC risk
(43,45). Conflicting results of these case-control studies
may be due to unknown interactions with environmental or
other genetic factors and may vary according to the choice
of polymorphisms to be genotyped. Bandiera et al (46)
demonstrated that P450 1B1-Ser453 protein displays lower
intracellular protein levels and is degraded more rapidly
than the other P450 1B1 variants. They concluded that it is
probable that individuals with the CYP1B1-Ser453 allele
have reduced metabolic activation of some endogenous (e.g.
estrogens) and exogenous (e.g. PAHs or heterocyclic amines)
carcinogens. Indeed, carriers of the variant CYP1B1 Ser/Ser
genotype in codon 453 showed a significantly reduced
incidence of endometrial cancer compared with homozygotes
who carried Asn at this position (OR=0.62; 95% CI=0.43-0.91)
(47).
In conclusion, our study identified polymorphisms in
CYP1B1, GSTM1 and GSTT1 as modifiers of CRC risk in the
Czech population. If verified by independent studies, these
polymorphisms might be used for identification of high-risk
individuals. Preventive screening programs and interventions
to prevent the development of CRC could then be targeted to
these individuals.
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